When you say it’s not yet practical, are we missing some key steps, or could it be done at high enough cost with current technology but can’t scale?
I imagine a startup which cured rich people’s cancers on a case by case basis would have a lot of customers, which would help drive prices down as the technology improved.
Makes sense thanks!
I imagine a startup of this ilk could be based in Prospera, which wouldn’t be a problem for the wealthy few to travel there for personalised treatment.
I also imagine that with a lighter regulatory regime, no need to scale up production, and no need for lengthy trials, developing a monoclonal antibody would be much quicker and cheaper. Consider how quickly COVID vaccines were found compared to when they were ready for use.
The other hurdles sound significant though.